We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$159M
1-Year Est. Return
60.94%
This Fund
S&P 500
This Quarter
Est. Return
+23.73%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$17.2M
(+17%)
Cap. Flow
+$3.07M
Cap. Flow
% of AUM
2.63%
Top 10 Holdings %
Top 10 Hldgs %
83.88%
Holding
24
New
8
Increased
4
Reduced
4
Closed
4
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
+$5.28M |
| 2 |
Kyverna Therapeutics
KYTX
|
+$4.95M |
| 3 |
IVA
Inventiva
IVA
|
+$4.65M |
| 4 |
Oculis Holding
OCS
|
+$3.46M |
| 5 |
Phathom Pharmaceuticals
PHAT
|
+$2.68M |
Top Sells
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$10.9M |
| 2 |
APLT
Applied Therapeutics
APLT
|
+$6.83M |
| 3 |
TScan Therapeutics
TCRX
|
+$3.52M |
| 4 |
Jasper Therapeutics
JSPR
|
+$2.45M |
| 5 |
Milestone Pharmaceuticals
MIST
|
+$2.17M |
Sector Composition
| 1 | Healthcare | 79.21% |
| 2 | Energy | 20.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Plains GP Holdings
PAGP
$4.97B
| $24.4M | 20.79% |
1,272,360
| – | – |
|
2
Achieve Life Sciences
ACHV
$650M
| $18.8M | 16.07% |
3,786,425
| – | – |
|
|
3
Phathom Pharmaceuticals
PHAT
$881M
| $12.3M | 10.49% |
740,918
+187,991
| +34% | +$2.68M |
|
|
4
Viridian Therapeutics
VRDN
$2.1B
| $8.79M | 7.51% |
282,531
+192,531
| +214% | +$5.28M |
|
|
5
Milestone Pharmaceuticals
MIST
$158M
| $8.32M | 7.1% |
4,118,321
-1,006,569
| -20% | -$2.17M |
|
|
6
Kyverna Therapeutics
KYTX
$473M
| $6.27M | 5.35% |
+666,666
| New | +$4.95M |
|
|
CMPS
7
Compass Pathways
CMPS
$1.8B
| $5.95M | 5.08% |
861,778
+351,778
| +69% | +$2.15M |
|
|
IVA
8
Inventiva
IVA
$1.04B
| $4.65M | 3.97% |
+1,000,000
| New | +$4.65M |
|
9
Delcath Systems
DCTH
$455M
| $4.43M | 3.78% |
438,509
| – | – |
|
10
Abeona Therapeutics
ABEO
$415M
| $4.38M | 3.74% |
830,780
-143,242
| -15% | -$721K |
|
11
Celldex Therapeutics
CLDX
$3.01B
| $4.19M | 3.58% |
154,300
-700
| -0.5% | -$18.4K |
|
12
Nektar Therapeutics
NKTR
$2.31B
| $3.5M | 2.99% |
82,822
+33,822
| +69% | +$1.89M |
|
|
13
Oculis Holding
OCS
$792M
| $3.45M | 2.95% |
+172,839
| New | +$3.46M |
|
14
SAB Biotherapeutics
SABS
$277M
| $2.44M | 2.08% |
+652,881
| New | +$2.15M |
|
15
Regenxbio
RGNX
$634M
| $1.68M | 1.44% |
+116,896
| New | +$1.46M |
|
|
LONA
16
LeonaBio Inc
LONA
$80.1M
| $1.13M | 0.96% |
149,279
| – | – |
|
|
LENZ
17
LENZ Therapeutics
LENZ
$156M
| $945K | 0.81% |
+59,085
| New | +$1.72M |
|
|
AARD
18
Aardvark Therapeutics
AARD
$146M
| $609K | 0.52% |
+46,408
| New | +$579K |
|
19
Zevra Therapeutics
ZVRA
$766M
| $571K | 0.49% |
63,683
-168,191
| -73% | -$1.59M |
|
|
KLRS
20
Kalaris Therapeutics
KLRS
$115M
| $355K | 0.3% |
+42,053
| New | +$269K |
|
|
AKRO
21
DELISTED
Akero Therapeutics
AKRO
| – | – |
-228,884
| Closed | -$10.9M |
|
|
APLT
22
DELISTED
Applied Therapeutics
APLT
| – | – |
-11,285,420
| Closed | -$6.83M |
|
|
23
Jasper Therapeutics
JSPR
$19.4M
| – | – |
-1,028,806
| Closed | -$2.45M |
|
|
24
TScan Therapeutics
TCRX
$60.3M
| – | – |
-1,932,304
| Closed | -$3.52M |
|
Similar funds
OS
OC
JF
1L
USWIA
AWP
RWM
EWA